Skin structure infection therapeutics market to be worth $2,573.1 million

The skin structure infection therapeutics market has been forecast to increase at a compound annual growth rate (CAGR) of 0.8% through to 2019, to reach a total market value of $2,573.1 million.

The industry grew at an impressive CAGR of 7.3% between 2006 and 2011, improving on a total of $1,704.1 million in 2006, to be worth $2,419.5 million by 2011.

Growth within the skin structure infection therapeutics market can be attributed to the increase in the number of immunocompromised patients, growth in the elderly population, and the entry of new antibiotics which have better safety and efficacy profiles than the existing antibiotics to which patients have developed resistance.

With nearly 5.5 million incident cases in 2010, skin structure infections account for a major portion of the hospital-treated infection market.

The current skin structure infection therapeutics market is strong due to the presence of four branded antibiotics: Zyvox (linezolid), Cubicin (daptomycin), Vibativ (telavancin) and Tygacil (tigecycline). The market also has a number of generic antibiotics, such as levofloxacin piperacillin/tazobactam and vancomycin

There is a significant unmet need in the skin structure infection therapeutics market. Patients risk contracting Multidrug-resistant (MDR) infections and suffer higher levels of morbidity and mortality than in the past.

Most importantly, the number of therapeutic options for serious, life-threatening bacterial infections is limited due to the aforementioned multidrug resistance.

For more information on the skin structure infection therapeutics market, see the latest research: Skin Structure Infection Therapeutics Market Report

Follow us on Twitter @CandMResearch